[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.172.195.82. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Oral Presentations: American Head and Neck Society
August 2006

S012 Dendritic Cell (DC)-Based Vaccine for Patients With SCCHN Using Autologous Tumor Cells as Immunogens

Arch Otolaryngol Head Neck Surg. 2006;132(8):840. doi:10.1001/archotol.132.8.840-b

Objectives: The primary objective of this clinical trial for patients with stage III/IV resectable squamous cell carcinoma of the head and neck (SCCHN) was to demonstrate the feasibility and safety of a vaccine prepared by feeding apoptotic autologous tumor (AuTu) cells to dendritic cells (DCs) and delivered intranodally under ultrasound guidance. The secondary objective was to demonstrate immune responses to the vaccine using interferon gamma (IFN-γ) ELISPOT assays.

×